Having had to give up on its liver disease ambitions due to a lack of funds, Hepion Pharmaceuticals has decided that its best option is to merge into Israeli biotech Pharma Two B.
Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...
Friday, Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) said it has begun winding down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as announced in December 2023.
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
Hepion Strengthens Board of Directors with Appointment of Michael Purcell
Hepion Announces Exercise of Warrants for $2.0M Aggregate Gross Proceeds
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic...
Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account...
Hepion Pharmaceuticals said Thursday it will seek strategic alternatives to keep its Phase IIb NASH drug development program alive alongside news that its CEO has resigned “for personal reasons.”
Hepion Pharmaceuticals is trying to stay afloat as the biotech’s CEO hits the exit and the company seeks strategic alternatives, leaving the fate of a phase 2b trial for non-alcoholic steatohepatitis (NASH) up in the air.